ARVN vs. GERN, DYN, RYTM, RNA, MRVI, PTCT, INDV, VERA, ARDX, and CORT
Should you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include Geron (GERN), Dyne Therapeutics (DYN), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Maravai LifeSciences (MRVI), PTC Therapeutics (PTCT), Indivior (INDV), Vera Therapeutics (VERA), Ardelyx (ARDX), and Corcept Therapeutics (CORT). These companies are all part of the "pharmaceutical preparations" industry.
Arvinas (NASDAQ:ARVN) and Geron (NASDAQ:GERN) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.
Geron received 308 more outperform votes than Arvinas when rated by MarketBeat users. Likewise, 69.52% of users gave Geron an outperform vote while only 65.27% of users gave Arvinas an outperform vote.
Arvinas has a net margin of -185.09% compared to Geron's net margin of -38,730.00%. Arvinas' return on equity of -64.79% beat Geron's return on equity.
Arvinas has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500. Comparatively, Geron has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.
Arvinas currently has a consensus price target of $61.13, suggesting a potential upside of 89.09%. Geron has a consensus price target of $6.10, suggesting a potential upside of 56.41%. Given Arvinas' stronger consensus rating and higher possible upside, equities analysts plainly believe Arvinas is more favorable than Geron.
In the previous week, Arvinas had 28 more articles in the media than Geron. MarketBeat recorded 31 mentions for Arvinas and 3 mentions for Geron. Geron's average media sentiment score of 0.85 beat Arvinas' score of 0.15 indicating that Geron is being referred to more favorably in the news media.
95.2% of Arvinas shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 5.2% of Arvinas shares are held by company insiders. Comparatively, 3.0% of Geron shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Geron has lower revenue, but higher earnings than Arvinas. Geron is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.
Summary
Arvinas beats Geron on 12 of the 18 factors compared between the two stocks.
Get Arvinas News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
